News | July 23, 2024
RPG Life Sciences posts Q1 FY25 PAT higher at Rs. 26.76 Cr
RPG Life Sciences has reported total income of Rs. 167.79 crores during the period ended June 30, 2024
RPG Life Sciences has reported total income of Rs. 167.79 crores during the period ended June 30, 2024
Contepo offers a unique mechanism of action and has the potential to address increasing antibiotic resistance and gaps in the current antibiotic treatment landscape
Phase III ARANOTE trial met primary endpoint, significantly increasing radiological progression-free survival (rPFS) with NUBEQA plus androgen deprivation therapy (ADT) compared to placebo plus ADT
dsm-firmenich decided to de-prioritize certain business segments, including the MEG-3 business
Multidisciplinary central team deployed to assist Gujarat with epidemiological, environmental, and laboratory investigations of AES cases
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
Rusan’s API facility in Ankleshwar is GMP approved by other stringent international agencies as well
Finance Minister Nirmala Sitharaman is set to present the full budget for the current financial year on July 23
This transaction is the third acquisition by three different Japanese players in this segment
Cyclosporine Ophthalmic Nanoemulsion is a preservative-free Nanoemulsion that has been approved in South Korea, Peru and several countries in the Middle East for treatment of dry eye syndrome
Subscribe To Our Newsletter & Stay Updated
